Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 499 results for "Tecfidera"

Biogen Idec Announces Strides In Clinical Studies For MS Treatments
Bioresearch Online

Biogen Idec announces encouraging data from Phase III multiple...

Biogen Idec, a biotechnology company, has announced that five-year data from the ENDORSE Phase III extension study show TECFIDERA provides sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis, or RRMS., 1 week ago

17 images for Tecfidera

Pharma Letter, 2 weeks ago
Drug Discovery and Development, 2 weeks ago
Nasdaq, 2 weeks ago
FDA News, 3 weeks ago, 2 months ago
Pharma Letter, 2 months ago
ABC News 4 Charleston, 2 months ago
Market Pulse Navigator, 3 months ago
I Stock Analyst, 3 months ago
ABC News 4 Charleston, 3 months ago
Pharma Letter

Dimethyl fumarate (Tecfidera) follow on study

11 September 2014 Author: Results from a five year follow on study show dimethyl fumarate remained effective over that period and there was no increased risk of side effects. People who started treatment when newly diagnosed showed most ...
 Multiple Sclerosis Trust2 weeks ago Strong and sustained efficacy reported for Tecfidera over five years12-09-2014  Pharma Letter2 weeks ago Biogen Idec's Phase 3 Study With Tecfidera Show Positive Data Over 5 Years  RTTNews.com2 weeks ago Biogen Idec, Inc. (Massachusetts) Release: New Data From ENDORSE Show Positive Results Continued Over Five Years With TECFIDERA® (Dimethyl Fumarate) In A Wide Range Of Multiple Sclerosis Patients  BioSpace2 weeks ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago
Pharma Letter

The Launch Of Five Immunomodulatory Therapies For Relapsing Forms Of Multiple Sclerosis Will Contribute To 4 Percent Annual Growth Of The Total Market From 2013 To 2023

BURLINGTON, Mass. Other key findings from the Pharmacor report entitled Multiple Sclerosis: U.S. market dominance of Tecfidera: With greater cross-trial efficacy on relapses than injectable agents, few serious safety risks or monitoring ...
 TheStreet.com1 month ago MS market to reach $20 billion in 2023 boosted by five new therapies  Pharma Letter1 month ago
Investor's Business Daily

Biotech Gets A Lift On Popular Drug, Strong Pipeline

at 19:13 PM EDT The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment.
 Industrial Info Financials1 month ago

BIOGEN IDEC : Sales of Biogen MS pill pick up steam overseas

AFTER DEBUTING in April 2013 and becoming one of the most successful drug launches ever in the US, the MS treat- ment Tecfidera shows no sign of slowing down. Tecfidera boasted second-quarter sales of $700 million worldwide, handily beating analyst ...
 4 Traders1 week ago Sales of Biogen MS pill pick up steam overseas [Medical Marketing and Media]  TMC Net1 week ago THE FINAL CUT [Medical Marketing and Media]  TMC Net1 week ago

Taking dimethyl fumarate (Tecfidera)

12 September 2014 Author: People were more likely to keep taking dimethyl fumarate if they had had pre-treatment information on benefits and side effects and built up the dose slowly to avoid side effects. Reported at the ACTRIMS / ECTRIMS ...
 Multiple Sclerosis Trust2 weeks ago Dimethyl fumarate (Tecfidera) approved in England and Wales  Multiple Sclerosis Trust1 month ago New oral MS treatment Tecfidera approved for use in England and Wales  Multiple Sclerosis Society1 month ago Dimethyl fumarate (BG-12, Tecfidera) - NICE confirms approval in final guidance  Multiple Sclerosis Trust1 month ago
FDA News

NICE Recommends MS Drug Tecfidera

Biogen Idec said it will launch its multiple sclerosis drug Tecfidera within three months in England and Wales following a final coverage recommendation from the UK healthcare pricing watchdog. The National Institute for Health and Care ...
 FDA News3 weeks ago dimethyl fumarate (Tecfidera)  MedicineNet.com1 month ago Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar Tecfidera  FiercePharma1 month ago Denmarks Forward Pharma to launch IP attack on Biogen Idecs MS superstar Tecfidera  Big News Network1 month ago

NICE recommends Biogen Idec's Tecfidera for multiple sclerosis27-08-2014

The UK's drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended Tecfidera (dimethyl fumarate) in the treatment of multiple sclerosis, developed by US biotech firm Biogen Idec (Nasdaq: BIIB) following a final ...
 Pharma Letter1 month ago NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)  FirstWord Pharma1 month ago NICE confirms recommendation for Biogen MS pill  Big News Network1 month ago NICE final yes for Biogen's MS pill  Pharmafocus1 month ago

Report Approved drugs by Bay State biotechs up 13 percent since 2010

Biogen's Tecfidera is one of the largest and most successful of the drugs developed by Massachusetts-based firms and approved in the past five years, helping boost the total number of
 Big News Network1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less